Erschienen in:
13.08.2020 | Inflammatory Bowel Disease (G Lichtenstein, Section Editor)
Update on Pregnancy in Patients with IBD
verfasst von:
Rachel W. Winter, MD, MPH, Sonia Friedman, MD
Erschienen in:
Current Treatment Options in Gastroenterology
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose of review
This review summarizes the most current clinical research and latest clinical guidelines in managing inflammatory bowel disease (IBD) before, during, and after pregnancy.
Recent findings
Recent guidelines emphasize the safety of thiopurines and biologics during pregnancy and nursing. Patients should be in remission for 3–6 months prior to conceiving and remain in remission to decrease the risk of poor pregnancy outcomes. Fertility is decreased in women with active IBD and in women who have had anal or rectal resection. Women with IBD, especially those with Crohn’s disease (CD) who have had surgery, have an increased time to pregnancy. Women with CD and ulcerative colitis who need assisted reproduction have a decreased chance of a live birth compared with women in the general population. Indications for caesarian section include active perianal disease.
Summary
Most IBD medications are safe during pregnancy and should be continued to ensure remission. Preconception counseling and a multidisciplinary team approach are the best ways to support a healthy pregnancy and delivery.